Last updated on October 2018

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available.


Brief description of study

The purpose of this open-label, single arm, multi-center Expanded Treatment Protocol (ETP) is to provide early access to ruxolitinib and evaluate safety information in patients with PV, who are HU resistant or intolerant and who have no other standard treatment option, nor do they qualify for another clinical study for PV.

Clinical Study Identifier: NCT02292446

Contact Investigators or Research Sites near you

Start Over

Novartis Investigative Site

A-1090 Vienna, Austria

Novartis Investigative Site

Rankweil, Austria

Novartis Investigative Site

Salzburg, Austria

Novartis Investigative Site

Antwerp, Belgium

Novartis Investigative Site

Brugge, Belgium

Novartis Investigative Site

Bruxelles, Belgium

Novartis Investigative Site

Leuven, Belgium

Novartis Investigative Site

Pleven, Bulgaria

Novartis Investigative Site

Plovdiv, Bulgaria

Novartis Investigative Site

Sofia, Bulgaria

Novartis Investigative Site

Vancouver, BC Canada

Novartis Investigative Site

Hamilton, ON Canada

Novartis Investigative Site

Santiago, Chile

Novartis Investigative Site

Bayonne, France

Novartis Investigative Site

Angers Cedex 1, France

Novartis Investigative Site

Avignon cedex 9, France

Novartis Investigative Site

Bordeaux, France

Novartis Investigative Site

Dunkerque, France

Novartis Investigative Site

Le Mans Cedex 09, France

Novartis Investigative Site

Marseille, France

Novartis Investigative Site

Meaux cedex, France

Novartis Investigative Site

Mulhouse cedex, France

Novartis Investigative Site

Nice Cedex, France

Novartis Investigative Site

Perpignan, France

Novartis Investigative Site

Pierre-Benite Cedex, France

Novartis Investigative Site

Pringy cedex, France

Novartis Investigative Site

Toulouse Cedex 9, France

Novartis Investigative Site

Vandoeuvre Les Nancy, France

Novartis Investigative Site

Villejuif Cedex, France

Novartis Investigative Site

Mannheim, Germany

Novartis Investigative Site

Aschaffenburg, Germany

Novartis Investigative Site

Augsburg, Germany

Novartis Investigative Site

Bad Soden, Germany

Novartis Investigative Site

Berlin, Germany

Novartis Investigative Site

Bottrop, Germany

Novartis Investigative Site

Eisenach, Germany

Novartis Investigative Site

Erlangen, Germany

Novartis Investigative Site

Frankfurt, Germany

Novartis Investigative Site

Friedrichshafen, Germany

Novartis Investigative Site

Hamburg, Germany

Novartis Investigative Site

Heidelberg, Germany

Novartis Investigative Site

Heilbronn, Germany

Novartis Investigative Site

Koblenz, Germany

Novartis Investigative Site

Mutlangen, Germany

Novartis Investigative Site

Stuttgart, Germany

Novartis Investigative Site

Wuerzburg, Germany

Novartis Investigative Site

Monterrey, Mexico

Novartis Investigative Site

Fredrikstad, Norway

Novartis Investigative Site

Braga, Portugal

Novartis Investigative Site

Coimbra, Portugal

Novartis Investigative Site

Lisboa, Portugal

Novartis Investigative Site

Singapore, Singapore

Novartis Investigative Site

Uddevalla, Sweden

Novartis Investigative Site

Khon Kaen, Thailand

Novartis Investigative Site

Bangkok, Thailand

Novartis Investigative Site

Chiang Mai, Thailand

Novartis Investigative Site

Viña del Mar, Chile

Novartis Investigative Site

Chambéry Cedex, France

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.